Answers are grounded in this paper and cite their sources.
In this cohort study, drug survival was comparable between adalimumab, infliximab, and ustekinumab but significantly lower for etanercept. There were no differences in drug survival among biologic-naive and nonnaive patients.
No takes yet. Share an insight, caveat, or question.
Ring et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: